Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUDCA as add-on treatment in ALS
NCT03800524Phase 3Unknown
- Sponsor
- Humanitas Research Hospital
- Start
- Feb 2019
- Primary completion
- Dec 2023
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of tauroursodeoxycholic acid in amyotrophic lateral sclerosis (ALS), sponsored by Humanitas Research Hospital. Status: unknown.
02
Drugs
tauroursodeoxycholic acid
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03800524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800524.